7:30 AM – 8:20 AM at the W Hotel, Great Room
8:40 AM Stage III Unresectable
8:50 AM PD-(L)1 Monotherapy for NSCLC
9:00 AM Chemotherapy + PD-(L)1 for NSCLC
9:10 AM PD-(L)1 + CTLA4 +/- Chemotherapy
9:20 AM Antibody Drug Conjugates + IO Combinations in NSCLC
9:30 AM Case Study
9:40 AM Q&A
10:00 AM – 10:30 AM ACL Live, Music Porch and W Hotel, Prefunction Hall
10:30 AM Limited Stage SCLC
10:40 AM 1L Extensive Stage SCLC
10:50 AM 2L+ SCLC
11:00 AM SCLC Biomarkers
11:10 AM Mesothelioma
11:20 AM Thymic Malignancies
11:30 AM Case Study
11:40 AM Q&A
12:10 AM – 1:40 PM W Hotel, Great Room
1:40 PM Biomarkers: What is NGS?
1:50 PM 1L EGFR
2:00 PM EGFR Exon 20 and Atypical Mutations
2:10 PM Overcoming EGFR TKI Resistance
2:20 PM HER2 in NSCLC
2:30 PM MET for NSCLC: TKI and ADC
2:40 PM Case Study
2:50 PM Q&A
3:10 PM – 3:40 PM ACL Live, Music Porch and W Hotel, Prefunction Hall
3:40 PM Liquid Biopsy in Lung Cancer
3:50 PM Artificial Intelligence in Lung Cancer
4:00 PM Translating Biomarkers to Better Outcomes in NSCLC
4:10 PM TTFields for the Thoracic Oncologist
4:20 PM Social Media for the Practicing Oncologist
4:30 PM Evolving Partnership with Patient Advocacy
4:40 PM Health Care Policy for Today’s Oncologist
4:50 PM Q&A
5:10 PM – 6:00 PM at ACL Live, General Session
7:30 AM – 8:20 AM at the W Hotel, Great Room
8:30 AM Duration of IO Therapy for Advanced NSCLC
8:40 AM Rechallenge with IO in NSCLC
8:50 AM Managing Brain Metastases in NSCLC
9:00 AM Toxicity and Contraindications for IO in NSCLC
9:10 AM IO and Targeted Therapy in NSCLC: Sequence, Toxicity
9:20 AM Biomarker Selection (STK11, KEAP1, PDL1) for IO in NSCLC
9:30 AM Case Study
9:40 AM Q&A
10:00 AM – 10:30 AM ACL Live, Music Porch and W Hotel, Prefunction Hall
10:30 AM ALK
10:40 AM ROS1/RET/NTRK/NRG1
10:50 AM BRAF
11:00 AM KRAS G12C
11:10 AM Antibody Drug Conjugates
11:20 AM Case Study
11:30 AM Q&A
11:50 AM – 1:30 PM W Hotel, Great Room
1:30 PM Targeted Perioperative Therapy for Early-Stage NSCLC
1:40 PM Adjuvant IO Therapy for NSCLC
1:50 PM Neoadjuvant IO Therapy for NSCLC
2:00 PM Perioperative IO Therapy for NSCLC
2:10 PM Case Study
2:20 PM Q&A
2:50 PM – 3:00 PM ACL Live, Music Porch and W Hotel, Prefunction Hall
3:00 PM Impact of Adjuvant after Neoadjuvant
3:10 PM Surgical Implications of Neoadjuvant Therapy for NSCLC
3:20 PM Selection of Endpoints: Impact on Practice
3:30 PM Q&A
3:40 PM Perioperative Chemo+IO IS Superior To (Neo)Adjuvant Therapy In Early-Stage NSCLC
3:50 PM Perioperative Chemo+IO IS NOT Superior To (Neo)Adjuvant Therapy In Early-Stage NSCLC
